Anca D. Askanase

Dec 10, 2024 | medscape.com | Anca D. Askanase

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Returning from the 2024 ACR Convergence, Dr Askanase highlights the presentation of the new 2024 American College of Rheumatology guidelines for lupus nephritis as the most impactful session at this year’s meeting.

Nov 7, 2024 | medscape.com | Anca D. Askanase

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Anca D.

May 22, 2024 | lupus.bmj.com | Anca D. Askanase |Richard A. Furie |Maria Dall'Era |Andrew Bomback

Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Oct 12, 2023 | ard.bmj.com | Joo-Young Lee |Arielle Mendel |Anca D. Askanase |Sang-Cheol Bae

Handling editor Josef S SmolenPresented at Prior conference presentation and published abstracts1. Lee JYE, Mendel A, Askanase A, Bae S, Buyon J et al. 'Systemic lupus erythematosus Women with lupus nephritis In pregnancy Therapeutic CHallenge (SWITCH)': The Systemic Lupus International Collaborating Clinics experience. American College of Rheumatology (ACR) Convergence 2022 – Philadelphia, PA, USA. 10–14 November 2022. Arthritis & Rheumatology.

Jul 25, 2023 | lupus.bmj.com | Elaine Karis |Joan T Merrill |Anca D. Askanase |Sandra Garces

Adaptive design of the phase IIb trials for rozibafusp alfa and efavaleukin alfa in SLEAn adaptive design is being used in two ongoing phase IIb double-blind, placebo-controlled, dose-ranging, multicentre studies at Amgen evaluating the safety and efficacy of rozibafusp alfa (AMG 570) (NCT04058028) and efavaleukin alfa (AMG 592) (NCT04680637).